Literature DB >> 18690494

Clinical markers of therapeutic response to disease modifying drugs.

Carlo Pozzilli1, Luca Prosperini.   

Abstract

Interferon beta (IFNbeta) and glatiramer acetate (GA) showed a relevant impact in modifying the clinical course of relapsing-remitting multiple sclerosis. However, not all treated patients experience a satisfied response to therapy in terms of suppression of relapse and slowing disability progression.At the present time none of the proposed criteria of response to disease modifying therapies (DMTs) have been validated. Clinical parameters, such as relapse rate and disability progression assessing with EDSS scale, may represent two useful indicators of therapeutic response, but their value in predicting the long-term response to DMTs is weak.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18690494     DOI： 10.1007/s10072-008-0939-9

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


  17 in total

1.  Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.

Authors:  Jordi Río; Carlos Nos; Mar Tintoré; Nieves Téllez; Ingrid Galán; Raúl Pelayo; Manuel Comabella; Xavier Montalban
Journal:  Ann Neurol       Date:  2006-02       Impact factor: 10.422

2.  The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability.

Authors:  B G Weinshenker; B Bass; G P Rice; J Noseworthy; W Carriere; J Baskerville; G C Ebers
Journal:  Brain       Date:  1989-02       Impact factor: 13.501

3.  A 6-year clinical and MRI follow-up study of patients with relapsing-remitting multiple sclerosis treated with Interferon-beta.

Authors:  A Paolillo; C Pozzilli; E Giugni; V Tomassini; C Gasperini; M Fiorelli; C Mainero; M Horsfield; S Galgani; S Bastianello; C Buttinelli
Journal:  Eur J Neurol       Date:  2002-11       Impact factor: 6.089

4.  Relapses and progression of disability in multiple sclerosis.

Authors:  C Confavreux; S Vukusic; T Moreau; P Adeleine
Journal:  N Engl J Med       Date:  2000-11-16       Impact factor: 91.245

5.  Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.

Authors:  L Kappos; A Traboulsee; C Constantinescu; J-P Erälinna; F Forrestal; P Jongen; J Pollard; M Sandberg-Wollheim; C Sindic; B Stubinski; B Uitdehaag; D Li
Journal:  Neurology       Date:  2006-09-26       Impact factor: 9.910

6.  Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Contribution of relapses to disability in multiple sclerosis.

Authors:  Claire Hirst; Gillian Ingram; Owen Pearson; Trevor Pickersgill; Neil Scolding; Neil Robertson
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

8.  Effect of relapses on development of residual deficit in multiple sclerosis.

Authors:  Fred D Lublin; Monika Baier; Gary Cutter
Journal:  Neurology       Date:  2003-12-09       Impact factor: 9.910

9.  Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.

Authors: 
Journal:  Neurology       Date:  1993-04       Impact factor: 9.910

10.  Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Authors:  L D Jacobs; D L Cookfair; R A Rudick; R M Herndon; J R Richert; A M Salazar; J S Fischer; D E Goodkin; C V Granger; J H Simon; J J Alam; D M Bartoszak; D N Bourdette; J Braiman; C M Brownscheidle; M E Coats; S L Cohan; D S Dougherty; R P Kinkel; M K Mass; F E Munschauer; R L Priore; P M Pullicino; B J Scherokman; R H Whitham
Journal:  Ann Neurol       Date:  1996-03       Impact factor: 10.422
View more
  6 in total

Review 1.  Treatment update in multiple sclerosis.

Authors:  Katrina Morris; Con Yiannikas
Journal:  Curr Allergy Asthma Rep       Date:  2012-06       Impact factor: 4.806

2.  Long-Term Effectiveness, Safety and Tolerability of Fingolimod in Patients with Multiple Sclerosis in Real-World Treatment Settings in France: The VIRGILE Study.

Authors:  Caroline Papeix; Giovanni Castelnovo; Emmanuelle Leray; Marc Coustans; Pierre Levy; Jean-Marc Visy; Gisela Kobelt; Fabienne Lamy; Bashar Allaf; François Heintzmann; Isabelle Chouette; Eric Raponi; Barbara Durand; Emmanuelle Grevat; Driss Kamar; Marc Debouverie; Christine Lebrun-Frenay
Journal:  Neurol Ther       Date:  2022-02-11

3.  Adoptive transfer of cytokine-induced immunomodulatory adult microglia attenuates experimental autoimmune encephalomyelitis in DBA/1 mice.

Authors:  Xing-Mei Zhang; Harald Lund; Sohel Mia; Roham Parsa; Robert A Harris
Journal:  Glia       Date:  2014-05       Impact factor: 7.452

4.  Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France.

Authors:  Christine Lebrun-Frenay; Antoine Moulignier; Charles Pierrot-Deseilligny; Rabah Benrabah; Thibault Moreau; Catherine Lubetzki; Françoise Monchecourt
Journal:  J Neurol       Date:  2019-02-07       Impact factor: 4.849

5.  Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?

Authors:  Zsolt Mezei; Daniel Bereczki; Lilla Racz; Laszlo Csiba; Tünde Csepany
Journal:  Neuropsychiatr Dis Treat       Date:  2012-10-23       Impact factor: 2.570

Review 6.  Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.

Authors:  Tamás Biernacki; Zsófia Kokas; Dániel Sandi; Judit Füvesi; Zsanett Fricska-Nagy; Péter Faragó; Tamás Zsigmond Kincses; Péter Klivényi; Krisztina Bencsik; László Vécsei
Journal:  Int J Mol Sci       Date:  2022-03-21       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.